Fredun Pharmaceuticals Reports 84% Q2 Income Growth in FY27
Key highlights
- Fredun Pharmaceuticals reported Q2 FY27 total income of ₹267.64 crore, up 84.21% year-on-year.
- Q2 FY27 EBITDA rose 90.74% to ₹42.60 crore, with margin improving 55 basis points to 15.92%.
- Q2 FY27 net profit increased 93.44% to ₹18.83 crore and net profit margin rose to 7.03%.
- H1 FY27 total income reached ₹495.88 crore, up 87.02% year-on-year.
powered by IRIS

Fredun Pharmaceuticals Limited reported Q2 FY27 total income of ₹267.64 crore, up 84.21% year-on-year, while EBITDA rose 90.74% to ₹42.60 crore and net profit increased 93.44% to ₹18.83 crore. The results for the quarter ended September 30, 2026 also showed improvement in operating and net profit margins.
Know Fredun Pharmaceuticals inside out
Results, valuation, peers and who's buying, in one view.
What did Fredun Pharmaceuticals report for Q2 FY27?
Fredun Pharmaceuticals reported total income of ₹267.64 crore in Q2 FY27, compared with ₹145.29 crore in the corresponding quarter of FY26. The 84.21% increase was accompanied by faster growth in EBITDA and net profit, indicating that profitability expanded alongside income during the quarter.
EBITDA was ₹42.60 crore, up 90.74% year-on-year, and the EBITDA margin improved by 55 basis points to 15.92%. Net profit rose 93.44% to ₹18.83 crore, while the net profit margin expanded by 34 basis points to 7.03%. These figures were presented during the company's Q2 and H1 FY27 earnings conference call held on November 16, 2026.
The company made the call recording available through its website following a disclosure to BSE under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations. The call covered unaudited results for the quarter and half year ended September 30, 2026.
How did Fredun Pharmaceuticals perform in the first half of FY27?
Fredun Pharmaceuticals recorded total income of ₹495.88 crore in H1 FY27, representing year-on-year growth of 87.02%. The first-half result broadly reflected the momentum reported in the second quarter, with earnings growth outpacing the increase in total income.
H1 EBITDA stood at ₹75.38 crore, up 91.67% year-on-year, and the EBITDA margin improved by 37 basis points to 15.20%. Net profit increased 93.92% to ₹31.99 crore. The net profit margin for the half year was 6.45%, according to the figures discussed on the conference call.
The reported margin movement is significant because both operating profit and net profit grew faster than total income in the periods disclosed. However, the call transcript does not provide a detailed numerical break-up of costs, product-wise income or segment-wise profitability.
What did management say about FY27 growth plans?
Fredun Pharmaceuticals management said the company had already overachieved its earlier FY27 revenue target of around ₹800 crore and expected to do better, but did not provide a revised revenue figure. Investors therefore have a management indication on the target, but no updated formal numerical guidance from the call.
Management attributed 30% to 40% of Q2 growth to new-age businesses. It also cited new territories in pet care and mobility, as well as third-party functional food orders, as additional contributors. The company said its established or “Vintage” businesses are expected to grow 15% to 20% year-on-year over the next seven to eight years, while new-age businesses are expected to grow around 65% to 70% annually.
The new-age portfolio mentioned on the call includes pet care, mobility, cosmetics, nutraceuticals and dermaceutics. Management noted that growth could vary by year, potentially reaching triple digits in some periods and falling below 60% in others as territories are added. These statements represent management expectations rather than reported financial results.
Got a follow-up? Ask IRIS
Which launches and operational developments did management disclose?
Fredun Pharmaceuticals said it plans to launch cat food in Q4 FY27, with management indicating a timeframe of about 60 to 90 days from the November 16 call. It also said CATICO brands are expected to reach markets across India over the next six to eight months.
Management said it hoped to have products present at 80% to 90% of relevant counters within the following year, subject to execution. In dermaceutics, it indicated that anti-aging products under the Dorsil brand could enter the market in about six to 18 months, initially across metro cities and later in tier-2 cities.
The company also disclosed that a chief financial officer was being trained and was expected to join in a few months. An internal audit team has been appointed. These steps point to ongoing additions to finance and control functions as the business expands, though no further details on the appointment or internal-audit structure were provided.
Why do the Q2 and H1 figures matter to investors?
Fredun Pharmaceuticals' Q2 and H1 results matter because income growth was paired with expansion in EBITDA and net profit margins. In Q2, EBITDA margin rose to 15.92% and net profit margin reached 7.03%, while H1 EBITDA margin was 15.20%. This means the company reported improved operating profitability during a period of rapid income growth.
Management described the next 18 to 24 months as the period in which a larger growth inflection could become visible, while also saying that an inflection may begin in the next few quarters. The statement should be assessed alongside actual execution in new-age businesses, new territory additions, product launches and the stated national expansion in pet care.
For investors, the key reported facts are the 84.21% Q2 income growth, the more than 90% growth in EBITDA and net profit, and the margin improvement. The key unresolved items are the revised FY27 target, absolute annual recurring revenue figures and the financial contribution expected from new launches, none of which were quantified in the call.
Conclusion
Fredun Pharmaceuticals delivered strong Q2 and H1 FY27 growth, with total income, EBITDA and net profit all increasing sharply year-on-year. The company also reported higher operating and net profit margins, suggesting that profitability improved alongside scale during the reported periods.
The next disclosures to watch are progress on the cat food launch, CATICO's distribution expansion, the planned Dorsil anti-aging launch and any revised FY27 revenue guidance. Management has indicated that a larger growth inflection could emerge over the next 18 to 24 months, but the call did not provide updated numerical targets for that period.


